Overview

A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2026-01-15
Target enrollment:
Participant gender:
Summary
It is a dose expansion, open-label, phase Ib study to evaluate the safety, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of CT103A in patients with relapsed/refractory multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Nanjing IASO Biotherapeutics Co.,Ltd